BMYNYSE
Bristol-Myers Squibb Company
$0.00
0.000.00%
15-min delay
E
Open—
Prev Close—
Market Cap$129.66B
P/E (TTM)13.96
EPS$6.15
Earnings2027-02-04
DAY RANGE
$0.00$0.00

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

SectorHealth Technology
Employees34100
ISINUS1101221083
AddressRoute 206 & Province Line Road, Princeton, NJ, 08543
Key Statistics
Full Stats
Market Cap$129.66B
Enterprise Value$161.01B
P/E Ratio (TTM)13.96
P/S Ratio2.60
P/B Ratio5.50
Forward P/E13.90
EPS (TTM)$4.51
EPS (FY)$6.15
Revenue (TTM)$50.05B
Profit Margin18.47%
Operating Margin32.93%
ROE40.53%
Debt/Equity1.91
Avg Vol (30d)11.1M
Beta (1Y)0.08
Beta (3Y)0.07
Beta (5Y)0.20
Shares Out2.04B
Float2.04B
Dividend3.97%
Next Earnings2027-02-04
Short Interest—
52-Week Range
$0.00
$45.27$68.64

Upgrades & Downgrades

Members

Every rating change, who made it, and what it moved from.

Sign in to viewCreate a free account

Free account. No card required.

Grades Consensus

Members

Analyst price targets — high, low, median and where it sits now.

Sign in to viewCreate a free account

Free account. No card required.

Price Target Consensus

Members

Analyst price targets — high, low, median and the upside from here.

Sign in to viewCreate a free account

Free account. No card required.

Ratings Snapshot

Members

DCF, Piotroski, Altman Z and returns scores, in one grade.

Sign in to viewCreate a free account

Free account. No card required.

Forward Estimates

Members

Quarterly revenue and EPS estimates, with the history of beats.

Sign in to viewCreate a free account

Free account. No card required.

Seasonality

Members

How this ticker has traded month by month over the last decade.

Sign in to viewCreate a free account

Free account. No card required.